Page last updated: 2024-08-21

quinazolines and nms p937

quinazolines has been researched along with nms p937 in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (60.00)	24.3611
2020's	4 (40.00)	2.80

Authors

Authors	Studies
Beria, I; Bossi, RT; Brasca, MG; Caruso, M; Ceccarelli, W; Fachin, G; Fasolini, M; Fiorentini, F; Forte, B; Pesenti, E; Pezzetta, D; Posteri, H; Re Depaolini, S; Scolaro, A; Valsasina, B	1
Alli, C; Alzani, R; Avanzi, N; Ballinari, D; Beria, I; Cappella, P; Caruso, M; Casolaro, A; Ciavolella, A; Cucchi, U; De Ponti, A; Felder, E; Fiorentini, F; Galvani, A; Gianellini, LM; Giorgini, ML; Isacchi, A; Lansen, J; Moll, J; Pesenti, E; Rizzi, S; Rocchetti, M; Sola, F; Valsasina, B	1
Albanese, C; Alzani, R; Amboldi, N; Bungaro, S; Casolaro, A; Cazzaniga, G; Ceruti, R; Cribioli, S; Giussani, U; Golay, J; Introna, M; Losa, M; Marchesi, F; Patton, V; Pesenti, E; Pezzoni, A; Rambaldi, A; Texido, G; Valsasina, B	1
Allen, M; Caron, HN; Clifford, SC; Den Boer, ML; Exalto, C; Hartsink-Segers, SA; Horstmann, M; Pieters, R; Williamson, D	1
Fanelli, M; Gudeman, B; Hattinger, CM; Michelacci, F; Picci, P; Sero, V; Serra, M; Tavanti, E; Valsasina, B; Vella, S; Versteeg, R	1
Armeson, K; Britten, C; Erlander, M; Ethier, S; Giordano, A; Kappler, C; Liu, Y; Park, Y; Reuben, J; Ridinger, M; Yeh, E	1
Ciotkowska, A; Erlander, MG; Hennenberg, M; Li, B; Ridinger, M; Rutz, B; Stief, CG; Tamalunas, A; Waidelich, R; Wang, R; Wang, X	1
Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L	1
Alimova, I; Balakrishnan, I; Donson, A; Erlander, M; Foreman, NK; Fosmire, S; Joshi, M; Madhavan, K; Pierce, A; Ridinger, M; Sullivan, KD; Venkataraman, S; Veo, B; Vibhakar, R; Wang, D	1
Croce, CM; Distefano, R; Gasparini, P; Kudo, M; Nigita, G; Veneziano, D; Zalles, N	1

Trials

1 trial(s) available for quinazolines and nms p937

Article	Year
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PloS one, 2013, Volume: 8, Issue:3 Topics: Adult; Animals; CD56 Antigen; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2013

Article

Year

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.

PloS one, 2013, Volume: 8, Issue:3

Topics: Adult; Animals; CD56 Antigen; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013

Other Studies

9 other study(ies) available for quinazolines and nms p937

Article	Year
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorganic & medicinal chemistry letters, 2011, May-15, Volume: 21, Issue:10 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Proliferation; Clinical Trials, Phase I as Topic; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2011
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Molecular cancer therapeutics, 2012, Volume: 11, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dogs; Female; Haplorhini; HL-60 Cells; Humans; Leukemia; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Rats; Xenograft Model Antitumor Assays	2012
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica, 2013, Volume: 98, Issue:10 Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Cohort Studies; Gene Knockdown Techniques; HEK293 Cells; Humans; Polo-Like Kinase 1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines	2013
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Investigational new drugs, 2014, Volume: 32, Issue:6 Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Osteosarcoma; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; RNA, Messenger; RNA, Small Interfering	2014
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PloS one, 2019, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2019
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α European journal of pharmacology, 2020, Apr-15, Volume: 873 Topics: Adrenergic alpha-2 Receptor Antagonists; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Synergism; Humans; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Piperazines; Polo-Like Kinase 1; Prostate; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Stromal Cells; Tumor Stem Cell Assay	2020
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:7 Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines	2021
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-oncology, 2022, 03-12, Volume: 24, Issue:3 Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Child; G2 Phase Cell Cycle Checkpoints; Humans; Medulloblastoma; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines	2022
Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells. Cell death and differentiation, 2022, Volume: 29, Issue:2 Topics: Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Humans; MicroRNAs; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines	2022